Search

Your search keyword '"Faustini, Sian E"' showing total 31 results
Start Over Author "Faustini, Sian E" Publication Year Range Last 3 years
31 results on '"Faustini, Sian E"'

3. Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination

Author

Faustini, Siân E., Cook, Alex, Hill, Harriet, Al-Taei, Saly, Heaney, Jennifer, Efstathiou, Elena, Tanner, Chloe, Townsend, Neal, Ahmed, Zahra, Dinally, Mohammad, Hoque, Madeeha, Goodall, Margaret, Stamataki, Zania, Plant, Timothy, Chapple, Iain, Cunningham, Adam F., Drayson, Mark T., Shields, Adrian M., and Richter, Alex G.

Published
2023
Full Text
View/download PDF

4. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

Author

Shields, Adrian M., Faustini, Sian E., Hill, Harriet J., Al-Taei, Saly, Tanner, Chloe, Ashford, Fiona, Workman, Sarita, Moreira, Fernando, Verma, Nisha, Wagg, Hollie, Heritage, Gail, Campton, Naomi, Stamataki, Zania, Klenerman, Paul, Thaventhiran, James E. D., Goddard, Sarah, Johnston, Sarah, Huissoon, Aarnoud, Bethune, Claire, Elcombe, Suzanne, Lowe, David M., Patel, Smita Y., Savic, Sinisa, Burns, Siobhan O., and Richter, Alex G.

Published
2022
Full Text
View/download PDF

5. Influence of individuals’ determinants including vaccine type on cellular and humoral responses to SARS-CoV-2 vaccination

Author

Chambers, Emma S., primary, Cai, Weigang, additional, Vivaldi, Giulia, additional, Jolliffe, David A., additional, Perdek, Natalia, additional, Li, Wenhao, additional, Faustini, Sian E., additional, Gibbons, Joseph M., additional, Pade, Corinna, additional, Richter, Alex G., additional, Coussens, Anna K., additional, and Martineau, Adrian R., additional

Published
2024
Full Text
View/download PDF

6. Influence of age, sex, body habitus, vaccine type and anti-S serostatus on cellular and humoral responses to SARS-CoV-2 vaccination

Author

Chambers, Emma S, primary, Cai, Weigang, additional, Cousens, Anna K, additional, Vivaldi, Giulia, additional, Jolliffe, David A, additional, Perdek, Natalia, additional, Li, Wenhao, additional, Faustini, Sian E, additional, Gibbons, Joseph M, additional, Pade, Corinna, additional, Richter, Alex G, additional, and Martineau, Adrian R, additional

Published
2023
Full Text
View/download PDF

8. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

Author

Ward, Kerensa E, primary, Steadman, Lora, additional, Karim, Abid R, additional, Reynolds, Gary M, additional, Pugh, Matthew, additional, Chua, Winnie, additional, Faustini, Sian E, additional, Veenith, Tonny, additional, Thwaites, Ryan S, additional, Openshaw, Peter J M, additional, Drayson, Mark T, additional, Shields, Adrian M, additional, Cunningham, Adam F, additional, Wraith, David C, additional, and Richter, Alex G, additional

Published
2023
Full Text
View/download PDF

11. Supplemental Material - Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE

Author

Reynolds, John A, Faustini, Sian E, Tosounidou, Sofia, Plant, Tim, Ubhi, Mandeep, Gilman, Rebecca, Richter, Alex G, and Gordon, Caroline

Subjects
111702 Aged Health Care, FOS: Health sciences
Abstract

Supplemental Material for Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE by John A Reynolds, Sian E Faustini, Sofia Tosounidou, Tim Plant, Mandeep Ubhi, Rebecca Gilman, Alex G Richter and Caroline Gordon in Lupus

Published
2023
Full Text
View/download PDF

12. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK)

Author

Jolliffe, David A., primary, Faustini, Sian E., additional, Holt, Hayley, additional, Perdek, Natalia, additional, Maltby, Sheena, additional, Talaei, Mohammad, additional, Greenig, Matthew, additional, Vivaldi, Giulia, additional, Tydeman, Florence, additional, Symons, Jane, additional, Davies, Gwyneth A., additional, Lyons, Ronan A., additional, Griffiths, Christopher J., additional, Kee, Frank, additional, Sheikh, Aziz, additional, Shaheen, Seif O., additional, Richter, Alex G., additional, and Martineau, Adrian R., additional

Published
2022
Full Text
View/download PDF

13. Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial

Author

Jolliffe, David A., primary, Vivaldi, Giulia, additional, Chambers, Emma S., additional, Cai, Weigang, additional, Li, Wenhao, additional, Faustini, Sian E., additional, Gibbons, Joseph M., additional, Pade, Corinna, additional, Coussens, Anna K., additional, Richter, Alex G., additional, McKnight, Áine, additional, and Martineau, Adrian R., additional

Published
2022
Full Text
View/download PDF

14. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)

Author

Jolliffe, David A, primary, Holt, Hayley, additional, Greenig, Matthew, additional, Talaei, Mohammad, additional, Perdek, Natalia, additional, Pfeffer, Paul, additional, Vivaldi, Giulia, additional, Maltby, Sheena, additional, Symons, Jane, additional, Barlow, Nicola L, additional, Normandale, Alexa, additional, Garcha, Rajvinder, additional, Richter, Alex G, additional, Faustini, Sian E, additional, Orton, Christopher, additional, Ford, David, additional, Lyons, Ronan A, additional, Davies, Gwyneth A, additional, Kee, Frank, additional, Griffiths, Christopher J, additional, Norrie, John, additional, Sheikh, Aziz, additional, Shaheen, Seif O, additional, Relton, Clare, additional, and Martineau, Adrian R, additional

Published
2022
Full Text
View/download PDF

15. Vitamin D status: a U-shaped relationship for SARS-CoV-2 seropositivity in UK healthcare workers

Author

Lugg, Sebastian T, primary, Mackay, William R, additional, Faniyi, Aduragbemi A, additional, Faustini, Sian E, additional, Webster, Craig, additional, Duffy, Joanne E, additional, Hewison, Martin, additional, Shields, Adrian M, additional, Parekh, Dhruv, additional, Richter, Alex G, additional, Scott, Aaron, additional, and Thickett, David R, additional

Published
2022
Full Text
View/download PDF

16. Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.

Author

Faustini, Sian E., Hall, Andrew, Brown, Sarah, Roberts, Sadie, Hill, Harriet, Stamataki, Zania, Jenner, Matthew W., Owen, Roger G., Pratt, Guy, Cook, Gordon, Richter, Alex, Drayson, Mark T., Kaiser, Martin F., and Heaney, Jennifer L. J.

Subjects
*COVID-19 pandemic, *BOOSTER vaccines, *MULTIPLE myeloma, *COVID-19, *SARS-CoV-2
Abstract

Summary: Multiple myeloma (MM) and anti‐MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID‐19) and other infections. We investigated anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) antibodies longitudinally in ultra‐high‐risk patients with MM receiving risk‐adapted, intensive anti‐CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross‐reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID‐19, even with intensive anti‐CD38 therapy for high‐risk MM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

Author

Ward, Kerensa E, primary, Steadman, Lora, additional, Karim, Abid R, additional, Reynolds, Gary M, additional, Pugh, Matthew, additional, Chua, Winnie, additional, Faustini, Sian E, additional, Veenith, Tonny, additional, Thwaites, Ryan S, additional, Openshaw, Peter JM, additional, Drayson, Mark T, additional, Shields, Adrian M, additional, Cunningham, Adam F, additional, Wraith, David C., additional, and Richter, Alex G, additional

Published
2022
Full Text
View/download PDF

19. SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation

Author

Lamerton, Rachel E., primary, Marcial-Juarez, Edith, additional, Faustini, Sian E., additional, Perez-Toledo, Marisol, additional, Goodall, Margaret, additional, Jossi, Siân E., additional, Newby, Maddy L., additional, Chapple, Iain, additional, Dietrich, Thomas, additional, Veenith, Tonny, additional, Shields, Adrian M., additional, Harper, Lorraine, additional, Henderson, Ian R., additional, Rayes, Julie, additional, Wraith, David C., additional, Watson, Steve P., additional, Crispin, Max, additional, Drayson, Mark T., additional, Richter, Alex G., additional, and Cunningham, Adam F., additional

Published
2022
Full Text
View/download PDF

20. Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study

Author

Shields, Adrian M, primary, Faustini, Sian E., additional, Hill, Harriet J., additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ashford, Fiona, additional, Workman, Sarita, additional, Moreira, Fernando, additional, Verma, Nisha, additional, Wagg, Hollie, additional, Heritage, Gail, additional, Campton, Naomi, additional, Stamataki, Zania, additional, Drayson, Mark T., additional, Klenerman, Paul, additional, Thaventhiran, James E. D., additional, Elkhalifa, Shuayb, additional, Goddard, Sarah, additional, Johnston, Sarah, additional, Huissoon, Aarnoud, additional, Bethune, Claire, additional, Elcombe, Suzanne, additional, Lowe, David M., additional, Patel, Smita Y., additional, Savic, Sinisa, additional, Richter, Alex G., additional, Burns, Siobhan O., additional, and Consortium, COVAD, additional

Published
2022
Full Text
View/download PDF

21. Vitamin D Supplements for Prevention of COVID-19 or other Acute Respiratory Infections: a Phase 3 Randomised Controlled Trial (CORONAVIT)

Author

Jolliffe, David A., primary, Holt, Hayley, additional, Greenig, Matthew, additional, Talaei, Mohammad, additional, Perdek, Natalia, additional, Pfeffer, Paul, additional, Vivaldi, Giulia, additional, Maltby, Sheena, additional, Symons, Jane, additional, Barlow, Nicola L., additional, Normandale, Alexa, additional, Garcha, Rajvinder, additional, Richter, Alex G., additional, Faustini, Sian E., additional, Orton, Christopher, additional, Ford, David, additional, Lyons, Ronan A., additional, Davies, Gwyneth A., additional, Kee, Frank, additional, Griffiths, Christopher J., additional, Norrie, John, additional, Sheikh, Aziz, additional, Shaheen, Seif O., additional, Relton, Clare, additional, and Martineau, Adrian R., additional

Published
2022
Full Text
View/download PDF

22. Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)

Author

Jolliffe, David A, primary, Faustini, Sian E, additional, Holt, Hayley, additional, Perdek, Natalia, additional, Maltby, Sheena, additional, Talaei, Mohammad, additional, Greenig, Matthew, additional, Vivaldi, Giulia, additional, Tydeman, Florence, additional, Symons, Jane, additional, Davies, Gwyneth A, additional, Lyons, Ronan A, additional, Griffiths, Christopher J, additional, Kee, Frank, additional, Sheikh, Aziz, additional, Shaheen, Seif O, additional, Richter, Alex G, additional, and Martineau, Adrian R, additional

Published
2022
Full Text
View/download PDF

23. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings From The COV-AD Study

Author

Shields, Adrian M, primary, Faustini, Sian E., additional, Hill, Harriet J., additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ashford, Fiona, additional, Workman, Sarita, additional, Moreira, Fernando, additional, Verma, Nisha, additional, Wagg, Hollie, additional, Heritage, Gail, additional, Campton, Naomi, additional, Stamataki, Zania, additional, Klenerman, Paul, additional, Goddard, Sarah, additional, Johnston, Sarah, additional, Huissoon, Aarnoud, additional, Bethune, Claire, additional, Elcombe, Suzanne, additional, Lowe, David M., additional, Patel, Smita Y., additional, Savic, Sinisa, additional, Burns, Siobhan O., additional, Richter, Alex G., additional, and Consortium, COV-AD, additional

Published
2022
Full Text
View/download PDF

24. Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic

Author

Chawla, Himanshi, primary, Jossi, Sian E., additional, Faustini, Sian E., additional, Samsudin, Firdaus, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Newby, Maddy L., additional, Marcial-Juárez, Edith, additional, Lamerton, Rachel E., additional, McLellan, Jason S., additional, Bond, Peter J., additional, Richter, Alex G., additional, Cunningham, Adam F., additional, and Crispin, Max, additional

Published
2022
Full Text
View/download PDF

25. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose

Author

Faustini, Sian E, primary, Shields, Adrian M, additional, Banham, Gemma, additional, Wall, Nadezhda, additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ahmed, Zahra, additional, Efstathiou, Elena, additional, Townsend, Neal, additional, Plant, Tim, additional, Perez-Toledo, Marisol, additional, Jasiulewicz, Aleksandra, additional, Price, Ruth, additional, McLaughlin, James, additional, Farnan, John, additional, Moore, Julie, additional, Robertson, Louise, additional, Nesbit, Andrew, additional, Curry, Grace, additional, Black, Amy, additional, Cunningham, Adam F, additional, Harper, Lorraine, additional, Moore, Tara, additional, Drayson, Mark T, additional, and Richter, Alex G, additional

Published
2022
Full Text
View/download PDF

26. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study

Author

Shields, Adrian M, primary, Venkatachalam, Srinivasan, additional, Shafeek, Salim, additional, Paneesha, Shankara, additional, Ford, Mark, additional, Sheeran, Tom, additional, Kelly, Melanie, additional, Qureshi, Iman, additional, Salhan, Beena, additional, Karim, Farheen, additional, De Silva, Neelakshi, additional, Stones, Jacqueline, additional, Lee, Sophie, additional, Khawaja, Jahanzeb, additional, Kaudlay, Praveen Kumar, additional, Whitmill, Richard, additional, Kakepoto, Ghulam Nabi, additional, Parry, Helen M, additional, Moss, Paul, additional, Faustini, Sian E, additional, Richter, Alex G, additional, Drayson, Mark T, additional, and Basu, Supratik, additional

Published
2021
Full Text
View/download PDF

27. In vitro, classical complement activation differs by disease severity and between SARS-CoV-2 antigens

Author

Lamerton, Rachel E, primary, Marcial Juarez, Edith, additional, Faustini, Sian E, additional, Perez-Toledo, Marisol E, additional, Goodall, Margaret, additional, Jossi, Sian E, additional, Newby, Maddy L, additional, Chapple, Iain, additional, Dietrich, Thomas, additional, Veenith, Tonny, additional, Shields, Adrian M, additional, Harper, Lorraine, additional, Henderson, Ian R, additional, Rayes, Julie, additional, Wraith, David C, additional, Watson, Steve P, additional, Crispin, Max, additional, Drayson, Mark T, additional, Richter, Alex G, additional, and Cunningham, Adam F, additional

Published
2021
Full Text
View/download PDF

28. Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK

Author

Shields, Adrian M, primary, Venkatachalam, Srinivasan, additional, Paneesha, Shankara, additional, Ford, Mark, additional, Sheeran, Tom, additional, Kelly, Melanie, additional, Karim, Farheen, additional, Qureshi, Iman, additional, Salhan, Beena, additional, DeSilva, Neelakshi, additional, Stones, Jacqueline, additional, Lee, Sophie, additional, Khawaja, Jahanzeb, additional, Kaudlay, Praveen Kumar, additional, Whitmill, Richard, additional, Nabikakepoto, Ghulam, additional, Faustini, Sian E, additional, Richter, Alex G, additional, Drayson, Mark T, additional, and Basu, Supratik, additional

Published
2021
Full Text
View/download PDF

29. Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Author

Jenner, Matthew W, primary, Hall, Andrew, additional, Faustini, Sian E, additional, Pitchford, Alexandra, additional, de Tute, Ruth M., additional, Roberts, Sadie, additional, Ingleson, Emma, additional, Bowles, Kristian M, additional, Garg, Mamta, additional, Lokare, Anand, additional, Messiou, Christina, additional, Jackson, Graham, additional, Pratt, Guy, additional, Cook, Gordon, additional, Owen, Roger G, additional, Brown, Sarah R, additional, Drayson, Mark T, additional, and Kaiser, Martin F., additional

Published
2021
Full Text
View/download PDF

30. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.

Author

Shields, Adrian M., Faustini, Sian E., Hill, Harriet J., Al-Taei, Saly, Tanner, Chloe, Ashford, Fiona, Workman, Sarita, Moreira, Fernando, Verma, Nisha, Wagg, Hollie, Heritage, Gail, Campton, Naomi, Stamataki, Zania, Drayson, Mark T., Klenerman, Paul, Thaventhiran, James E. D., Elkhalifa, Shuayb, Goddard, Sarah, Johnston, Sarah, and Huissoon, Aarnoud

Subjects
ANTIBODY formation, PRIMARY immunodeficiency diseases, SARS-CoV-2, COVID-19 vaccines, IMMUNIZATION
Abstract

Background: Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed to enhance their humoral and cellular immunity. Objectives: To determine the immunogenicity of the third primary SARS-CoV-2 immunisation in a heterogeneous cohort of patients with antibody deficiency. Methods: Participants enrolled in the COV-AD study were sampled before and after their third vaccine dose. Serological and cellular responses were determined using ELISA, livevirus neutralisation and ELISPOT assays. Results: Following a two-dose schedule, 100% of healthy controls mounted a serological response to SARS-CoV-2 vaccination, however, 38.6% of individuals with antibody deficiency remained seronegative. A third primary SARS-CoV-2 vaccine significantly increased anti-spike glycoprotein antibody seroprevalence from 61.4% to 76.0%, the magnitude of the antibody response, its neutralising capacity and induced seroconversion in individuals who were seronegative after two vaccine doses. Vaccine-induced serological responses were broadly cross-reactive against the SARS-CoV-2 B.1.1.529 variant of concern, however, seroprevalence and antibody levels remained significantly lower than healthy controls. No differences in serological responses were observed between individuals who received AstraZeneca ChAdOx1 nCoV-19 and Pfizer BioNTech 162b2 during their initial two-dose vaccine schedule. SARS-CoV-2 infectionnaive participants who had received a heterologous vaccine as a third dose were significantly more likely to have a detectable T cell response following their third vaccine dose (61.5% vs 11.1%). Conclusion: These data support the widespread use of third primary immunisations to enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study.

Author

Shields, Adrian M, Venkatachalam, Srinivasan, Shafeek, Salim, Paneesha, Shankara, Ford, Mark, Sheeran, Tom, Kelly, Melanie, Qureshi, Iman, Salhan, Beena, Karim, Farheen, De Silva, Neelakshi, Stones, Jacqueline, Lee, Sophie, Khawaja, Jahanzeb, Kaudlay, Praveen Kumar, Whitmill, Richard, Kakepoto, Ghulam Nabi, Parry, Helen M, Moss, Paul, and Faustini, Sian E

Subjects
VACCINE effectiveness, COVID-19 vaccines, BOOSTER vaccines, CONSORTIA, B cells, IMMUNE reconstitution inflammatory syndrome, AUTOIMMUNE diseases
Abstract

B-cell-depleting agents are among the most commonly used drugs to treat haemato-oncological and autoimmune diseases. They rapidly induce a state of peripheral B-cell aplasia with the potential to interfere with nascent vaccine responses, particularly to novel antigens. We have examined the relationship between B-cell reconstitution and SARS-CoV-2 vaccine responses in two cohorts of patients previously exposed to B-cell-depleting agents: a cohort of patients treated for haematological B-cell malignancy and another treated for rheumatological disease. B-cell depletion severely impairs vaccine responsiveness in the first 6 months after administration: SARS-CoV-2 antibody seroprevalence was 42.2% and 33.3% in the haemato-oncological patients and rheumatology patients, respectively and 22.7% in patients vaccinated while actively receiving anti-lymphoma chemotherapy. After the first 6 months, vaccine responsiveness significantly improved during early B-cell reconstitution; however, the kinetics of reconstitution was significantly faster in haemato-oncology patients. The AstraZeneca ChAdOx1 nCoV-19 vaccine and the Pfizer BioNTech 162b vaccine induced equivalent vaccine responses; however, shorter intervals between vaccine doses (<1 m) improved the magnitude of the antibody response in haeamto-oncology patients. In a subgroup of haemato-oncology patients, with historic exposure to B-cell-depleting agents (>36 m previously), vaccine non-responsiveness was independent of peripheral B-cell reconstitution. The findings have important implications for primary vaccination and booster vaccination strategies in individuals clinically vulnerable to SARS-CoV-2. B cell depleting drugs including rituximab are commonly used to treat haematological malignancy and autoimmune diseases but may impair the immunological response to vaccination. This study investigates SARS-CoV-2 vaccine responses in individuals with haematological and rheumatological disease with previously exposure to B cell depleting agents. Vaccination within the first 6 months of B cell depletion is associated with significant impairment of vaccine responsiveness; however, rheumatology and haemato-oncological patients display different kinetics of B cell reconstitution corresponding to differential vaccine responsiveness over time. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results